• 苹果高管驳斥iPhone计划报废说 iOS 12就是证据 2019-05-07
  • 热门楼盘趁势而入迎热销 红六月正式上线 ——凤凰网房产天津 2019-04-29
  • 国家税务总局:国地税改革进入具体实施操作阶段 2019-04-28
  • 习近平关于生态环境保护的十个精妙论述 2019-04-28
  • 生态环境部严厉打击转移倾倒固体废物及危险废物 2019-04-27
  • 马克思的每个人全面而自由发展,是人的最高需求层次理论。 2019-04-22
  • 空调还装墙壁上?聪明人都是往这里装,好看又省地 ——凤凰网房产 2019-04-22
  • 这下就真的更加坐实你的老蚕了,所有网友都是见证!想赖都赖不掉了。 2019-04-20
  • 空姐,到底要不要漂亮?-光明时评 2019-04-18
  • 沃尔沃全新S60高性能版官图曝光 2019-04-18
  • [视频]《乡村振兴战略大家谈》第六集4分钟精编版 2019-04-12
  • 赵哲春季写真大公开 百变风格切换自如 2019-04-07
  • “无中生有”也能助力文旅 2019-04-07
  • 坚守一条红线 维护生态安全(在习近平新时代中国特色社会主义思想指引下——新时代新作为新篇章) 2019-04-07
  • 中国石油呼和浩特石化公司获第十二届人民企业社会责任奖年度环保奖 2019-04-07
  • Select Page

    Healthcare and Pharmaceuticals

    Charltons provides high impact advice on corporate finance and capital markets transactions to PRC and international healthcare and pharmaceutical companies. We have long experience of bringing mainland Chinese companies to the Hong Kong market and were involved in some of the earliest listings of PRC pharmaceutical and biomedical companies on the Hong Kong Stock Exchange. Since then, we have become trusted outside general counsel to many listed healthcare and pharmaceutical companies, providing practical guidance on Hong Kong regulatory, compliance and disclosure issues. We also assist in respect of disclosure and reporting obligations of companies with dual Hong Kong and PRC listings.

    In addition to our capital markets practice, we also advise companies in the biomedical, healthcare and pharmaceutical sector across a broad range of corporate and commercial matters, including corporate restructurings, strategic acquisitions and divestments, equity and debt financing, joint ventures and investments, brand and intellectual property protection, licensing, employment issues and incentive schemes, and antitrust and bribery issues.

    We have a particular expertise in advising on investments and joint ventures in China. We have almost two decades of experience in China and have offices in Shanghai and Beijing, as well as long established relationships with top Chinese law firms in all of the major Chinese cities. Our deep local knowledge and international perspective allows us to provide smart and practical advice to foreign investors negotiating joint ventures and other investments in Chinese biomedical, healthcare and pharmaceutical markets.

    For foreign healthcare and pharmaceutical companies planning to enter China, we can undertake due diligence on their likely partner or target to find potential deal roadblocks. We also assess and provide strategic advice on regulatory issues arising from product development in China, including support on regulatory filings and developing strategies for meetings with regulatory bodies. As China grows as a base for global pharmaceutical companies to conduct R&D activities, we can advise on consortia, strategic cooperation and RD&D agreements. We have also assisted fund managers to establish investment funds targeting investments in the healthcare and pharmaceutical sectors in China.

    Although there have been relatively few “outbound” M&A transactions by Chinese pharmaceutical businesses to date, activity in the outbound market is increasing, driven by cash rich companies seeking strategic overseas acquisitions. We are particular strong in China-related “outbound” M&A transactions, providing support to Chinese acquiring companies in unfamiliar territories. We have acted on some of the most ground breaking outbound M&A deals in recent years, including one of the first takeovers of a UK listed company by a Chinese acquirer. We have experience in the particular challenges faced by Chinese companies in outbound M&A, from dealing with political sensitivities and investment restrictions on state owned enterprises in countries like the US and Australia to domestic concerns and regulatory approvals for outbound acquisitions that can complicate deal making and put Chinese bidders at a disadvantage, particularly in auction situations. The firm’s lawyers provide insightful and highly personalised service to clients, often working round the clock to deliver on transactions spanning multiple time zones.

     

    Regulation of pharmaceutical products in drugs in Hong Kong 

    The key laws regulating pharmaceutical products and drugs in Hong Kong include the Pharmacy and Poisons Ordinance (Cap. 138 of the Laws of Hong Kong) (“PPO”) which regulates the sale and labelling of products classified as pharmaceutical products and medicine and the Dangerous Drugs Ordinance (Cap. 134 of the Laws of Hong Kong) (“DDO”).

    Under the PPO, substances constituting “pharmaceutical products” as defined therein must be registered before it can be made available in Hong Kong. Further, the Pharmacy and Poisons Ordinance contains restrictions on sale and supply of pharmaceutical products depending on the category in which the relevant product appears in the Poisons List under the Poisons List Regulations (Cap. 138B of the Laws of Hong Kong). It also set out ways in which certain prescriptions must be handled.

    The DDO, on the other hand, regulates the import, export, procuring, supply, dealing, manufacturing and possession of substances constituting “dangerous drugs” as defined therein. Generally, dangerous drugs may not be supplied to persons who are not properly authorised or licensed to possess the same and must be administered by or under the direct supervision of registered medical practitioners.

    Charltons has experience in a range of corporate and commercial matters relating to the healthcare and pharmaceutical sector in Hong Kong and China, including equity and debt financing, joint ventures and investments, and healthcare due diligence.

    四句特码生肖诗:Healthcare and pharmaceutical

    Due diligence

    Pharmacy and Poisons Ordinance

    Hong Kong China Healthcare and pharmaceutical sector

    Healthcare and pharmaceutical corporate and commercial law

    Pharmacy and Poisons Ordinance Cap 138 of the Laws of Hong Kong PPO

    Legal advice for Hong Kong healthcare and pharmaceutical companies

    Investments and joint ventures in China

    Capital markets

    China related outbound M&A

    Dangerous Drugs Ordinance Cap 134 of the Laws of Hong Kong DDO

    Poisons List Regulations Cap 138B of the Laws of Hong Kong
    Healthcare basic due diligence checklist
    Due diligence checklist for acquisition
    Legal due diligence
    Due diligence compliance

    Privacy Preference Center

    Strictly Necessary

    Cookies that are necessary for the site to function properly.

    gdpr, PHPSESSID

    Performance

    These are used to track user interaction and detect potential problems. These help us improve our services by providing analytical data on how users use this site.

    _ga, _gat, _gid, _atuvc, _atuvs

  • 苹果高管驳斥iPhone计划报废说 iOS 12就是证据 2019-05-07
  • 热门楼盘趁势而入迎热销 红六月正式上线 ——凤凰网房产天津 2019-04-29
  • 国家税务总局:国地税改革进入具体实施操作阶段 2019-04-28
  • 习近平关于生态环境保护的十个精妙论述 2019-04-28
  • 生态环境部严厉打击转移倾倒固体废物及危险废物 2019-04-27
  • 马克思的每个人全面而自由发展,是人的最高需求层次理论。 2019-04-22
  • 空调还装墙壁上?聪明人都是往这里装,好看又省地 ——凤凰网房产 2019-04-22
  • 这下就真的更加坐实你的老蚕了,所有网友都是见证!想赖都赖不掉了。 2019-04-20
  • 空姐,到底要不要漂亮?-光明时评 2019-04-18
  • 沃尔沃全新S60高性能版官图曝光 2019-04-18
  • [视频]《乡村振兴战略大家谈》第六集4分钟精编版 2019-04-12
  • 赵哲春季写真大公开 百变风格切换自如 2019-04-07
  • “无中生有”也能助力文旅 2019-04-07
  • 坚守一条红线 维护生态安全(在习近平新时代中国特色社会主义思想指引下——新时代新作为新篇章) 2019-04-07
  • 中国石油呼和浩特石化公司获第十二届人民企业社会责任奖年度环保奖 2019-04-07